
    
      This study is a phase IV study in subjects with acute drug-induced liver injury. As designed,
      the study will include a screening period of up to 1 week, 2 to 4 weeks of treatment, and 1
      week of safety follow-up. The eligible subjects will randomly be assigned to polyene
      phosphatidylcholine group or magnesium isoglycyrrhizinate group to receive single-blind
      treatment with a ratio of 1:1.
    
  